NICE (UK) will support the use of Fractional exhaled Nitric Oxide (FeNO) measurement in diagnosis and management of asthma.

Solna (Sweden) – Aerocrine AB (OMX Nordic Exchange: AERO) today announced that NICE (National Institute for Health and Care Excellence) has notified stakeholders that the final guidelines recommending the use of Aerocrine’s NIOX MINO® and NIOX VERO® to improve diagnosis and management of a type of asthma caused by airway inflammation are expected to be published in April.

NICE develops evidence-based guidelines that help the National Health Services, local authorities and the wider medical community deliver high-quality healthcare to the British public. The new guidelines recommend that FeNO tests be used to assist with the diagnosis and management of asthma caused by allergic airway inflammation in adults and children who, after initial clinical examination, are considered to have an intermediate probability of having asthma and when FeNO testing is intended to be done in combination with other diagnostic options.

Aerocrine’s NIOX MINO® and NIOX VERO® measure FeNO levels. Healthcare professionals use FeNO testing to identify allergic airway inflammation in patients with suspected asthma, to help predict patient response to corticosteroid therapy and to help assess patient adherence to the prescribed therapy. NIOX MINO and NIOX VERO produce reliable and accurate results and are built on the recommendations from the American Thoracic Society (ATS) and the European Respiratory Society (ERS).

The Stakeholder Notification included the following information:

The guidelines will look at how NIOX MINO and NIOX VERO technologies can improve diagnosis and management of asthma.

The implementation pack, which includes case studies carried out in hospitals and GP surgeries, will provide useful information and practical advice on putting this guidance into practice. Respiratory clinicians from several NHS sites, who participated in the development of this pack, reported that benefits of adopting these technologies can include:

• Reduced numbers of non-elective admissions associated with asthma

• Reduced risk of readmission for patients admitted because of asthma after discharge from hospital

• Improved and earlier diagnosis of asthma in adults and children

• Reduced need for invasive lung function tests to diagnose or manage asthma

• Ease of use for patients and suitably trained staff  
  
  

Aerocrine will provide additional information once the final guidelines are published according to the dates given by NICE.

For more information, contact:

Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +46 768 788 379, +970 368 0336

David Plotts, Vice President, UK Managing Director and EU/RoW Sales.   +44 (0) 7891 433239

Dr. Kathy Rickard, Chief Medical Officer, Aerocrine AB +919 749 6708

About Aerocrine

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX VERO® (EU) Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany and the U.K. Aerocrine shares were listed on the Stockholm Stock Exchange in 2007.

Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 5:00 PM on 03/21/2014